Bristol Myers Squibb plans to invest $2.3 billion in a new advanced manufacturing campus at Generation Park in northeast Houston. The 600,000-square-foot facility is expected to create nearly 500 skilled permanent jobs and about 2,000 construction-related jobs, adding a major pharmaceutical manufacturing project to the Houston area.
Key Takeaways
- Bristol Myers Squibb announced a $2.3 billion investment in a new Houston manufacturing campus.
- The 600,000-square-foot facility will be built at Generation Park in northeast Houston.
- The project is expected to create nearly 500 skilled permanent jobs.
- Construction and related work are expected to involve about 2,000 jobs between 2027 and 2030.
- The facility is planned to manufacture small-molecule medicines, biologics and antibody-drug conjugates.
Bristol Myers Squibb Houston plans involve a $2.3 billion investment in an advanced manufacturing campus at Generation Park in northeast Houston. The project is expected to create nearly 500 skilled permanent jobs and about 2,000 construction-related jobs during the development period.
The investment will establish a new pharmaceutical manufacturing facility with a planned footprint of 600,000 square feet. The project represents a major manufacturing development for the Houston area and will add pharmaceutical production capacity at the Generation Park site.
The permanent positions are expected to be skilled jobs associated with operation of the manufacturing facility. Construction and related employment is expected to provide about 2,000 jobs between 2027 and 2030.
The scale of the investment and the number of positions associated with the project make the development relevant to Houston’s manufacturing workforce and the region’s pharmaceutical sector.
The facility is planned to support the production of multiple types of medicines. Its manufacturing capabilities will include small-molecule medicines, biologics and antibody-drug conjugates.
Houston’s existing biotechnology sector includes pharmaceutical developers and other life-sciences companies, with the city identified as one of several Texas hubs for biotechnology research and business activity.Â
Generation Park Selected for New Manufacturing Campus
Generation Park in northeast Houston has been selected as the location for the new Bristol Myers Squibb manufacturing campus. The site will accommodate the planned 600,000-square-foot facility.
The location places the project within the Houston area while establishing a dedicated site for advanced pharmaceutical manufacturing. Bristol Myers Squibb’s investment will add a large-scale manufacturing operation to the Generation Park development.
The project is centered on manufacturing rather than a general corporate or administrative facility. Its planned operations are specifically designed to produce medicines across several pharmaceutical categories.
The selection of Generation Park also defines the geographic location of the expected employment associated with the project. Construction jobs will be tied to development of the facility, while the nearly 500 permanent positions are expected to support the completed manufacturing operation.
The project will therefore involve two distinct employment phases. Construction and related work is expected to generate about 2,000 jobs between 2027 and 2030, followed by the operation of the completed facility and its expected permanent workforce.
For Houston, the development combines a substantial capital investment with a defined manufacturing footprint and employment commitment.
Texas has also recorded major corporate facility projects across manufacturing and other industries, with Houston among the state’s major metropolitan areas receiving large-scale business investment.Â
Facility Will Cover 600,000 Square Feet
The planned Bristol Myers Squibb facility will cover approximately 600,000 square feet. The size of the campus reflects the manufacturing function planned for the Generation Park site.
The facility will be designed for advanced pharmaceutical manufacturing. Its planned production capabilities include small-molecule medicines, biologics and antibody-drug conjugates.
Small-molecule medicines represent one category of pharmaceutical products covered by the planned operation. Biologics represent another category, while antibody-drug conjugates are also included in the facility’s planned manufacturing capabilities.
The combination of these production categories means the campus is being developed to support different pharmaceutical manufacturing processes rather than a single product type.
The $2.3 billion investment will fund development of the Houston campus associated with these manufacturing operations. The project is therefore tied directly to the construction and establishment of the new production facility.
The planned footprint also provides a clear physical scale for the development. At 600,000 square feet, the campus will constitute a substantial manufacturing project within Generation Park.
The facility’s manufacturing purpose and planned production categories distinguish the development from projects focused solely on offices, research activities or other non-manufacturing operations.
Texas manufacturing facilities are increasingly incorporating advanced technologies, including automation, sensors and data systems, into industrial operations.Â
Advanced Manufacturing Capabilities
The Houston campus is planned to manufacture small-molecule medicines, biologics and antibody-drug conjugates. These categories establish the types of pharmaceutical production expected to take place at the facility.
The planned capabilities are a central part of the project because the investment is specifically directed toward advanced manufacturing. The facility’s size and intended production scope are connected to that manufacturing role.
The project therefore combines a large physical facility with a defined pharmaceutical production purpose and an associated skilled workforce.
Project Brings Nearly 500 Permanent Jobs
Bristol Myers Squibb expects the Houston project to create nearly 500 skilled permanent jobs once the manufacturing campus is operating. Those positions will be associated with the facility’s long-term manufacturing activities.
The permanent employment figure is separate from the construction workforce expected during development. About 2,000 construction-related jobs are expected between 2027 and 2030.
The distinction between temporary construction employment and permanent positions provides two measurable employment components for the project. Construction-related work is connected to building the campus, while the nearly 500 permanent jobs are tied to ongoing operation of the manufacturing facility.
The employment figures also provide a direct measure of the project’s anticipated workforce impact in Houston.
For workers, the project includes opportunities during both the development phase and the planned long-term manufacturing operation. Construction and related jobs are expected during the 2027-to-2030 period, while the permanent workforce will support the facility after development.
The project consequently has a defined employment timeline tied to the construction and operation of the new campus.
The nearly 500 permanent positions also align with the facility’s role as an advanced pharmaceutical manufacturing operation. The jobs will support a campus designed to produce multiple categories of medicines.
Houston’s technology and healthcare sectors also include health-tech companies working across medical and technology fields, adding another established component to the city’s broader healthcare-related business base.Â
Construction Schedule Runs Through 2030
Construction and related work for the Bristol Myers Squibb campus is expected to involve about 2,000 jobs between 2027 and 2030. That period covers the development phase identified for the project.
The construction workforce will support development of the planned 600,000-square-foot manufacturing facility at Generation Park.
The 2027-to-2030 period is specifically associated with construction and related employment in the project details. It provides the stated timeframe for the development-related jobs rather than the operating period for the permanent workforce.
Once the manufacturing campus is completed and operating, the project is expected to support nearly 500 skilled permanent jobs.
The two employment figures therefore correspond to different stages of the project. Approximately 2,000 construction-related jobs are expected during development, while nearly 500 permanent jobs are expected from the completed manufacturing operation.
Texas Support for the Houston Project
The project is centered on Houston and its Generation Park location, with the investment directed toward a new pharmaceutical manufacturing campus.
The combination of the $2.3 billion capital commitment, 600,000-square-foot facility and expected employment establishes the project’s principal measurable elements.
The manufacturing operation is planned to produce small-molecule medicines, biologics and antibody-drug conjugates. Those capabilities give the facility a defined role within Bristol Myers Squibb’s manufacturing activities.
The project’s stated employment figures also establish its workforce component. About 2,000 construction-related jobs are expected between 2027 and 2030, while nearly 500 skilled permanent positions are expected from the completed facility.
Frequently Asked Questions
How much is Bristol Myers Squibb investing in Houston?
Bristol Myers Squibb plans to invest $2.3 billion in the new advanced manufacturing campus at Generation Park in northeast Houston.
Where will the Bristol Myers Squibb facility be built?
The facility will be built at Generation Park in northeast Houston.
How many jobs will the Houston facility create?
The project is expected to create nearly 500 skilled permanent jobs. Construction and related work is expected to involve about 2,000 jobs between 2027 and 2030.
What will Bristol Myers Squibb manufacture in Houston?
The planned facility will manufacture small-molecule medicines, biologics and antibody-drug conjugates.
When is construction expected to take place?
Construction and related employment are expected to run between 2027 and 2030.
